Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis
Identifieur interne : 000014 ( Main/Exploration ); précédent : 000013; suivant : 000015Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis
Auteurs : Nancy Ho-Mahler [États-Unis] ; Beni Turner [États-Unis] ; Michael Eaddy [États-Unis] ; Mark L. Hanke [États-Unis] ; Winnie W. Nelson [États-Unis]Source :
- Open Access Rheumatology : Research and Reviews [ 1179-156X ] ; 2020.
Abstract
Repository corticotropin injection (RCI) is indicated for a number of autoimmune-mediated diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and dermatomyositis (DM)/polymyositis (PM). To better understand the practice patterns and outcomes of RCI in patients with RA, SLE, or DM/PM, we conducted a retrospective medical record analysis.
Participating providers selected deidentified medical records of patients meeting the inclusion criteria (age ≥18 years; physician-reported diagnosis of RA, SLE, or DM/PM; initiation of treatment with RCI between 1/1/2011 and 2/15/2016; ≥3 in-office visits with same site/provider). Collected data spanned 12 months before and after the first prescription date for RCI. Analyses included patient demographics and clinical history, RCI treatment patterns, and physician’s impression of change.
Data from 54 patients with RA, 30 patients with SLE, and 8 patients with DM/PM were analyzed. The most frequently reported reasons for initiating RCI were lack of efficacy with prior treatment, acute exacerbation of disease, and use as add-on to ongoing therapy. The most common initial RCI dosing, 80 U twice weekly, was used for 84% of patients with RA, 75% with SLE, and 86% with DM/PM. The mean duration of treatment was 4.8, 6.5, and 6.8 months for RA, SLE, and DM/PM, respectively. Among the 57 patients with data on physician’s impression of change with RCI, 78.1% of patients with RA, 94.7% with SLE, and 66.7% with DM/PM had a rating of “improved,” and the mean time to best impression of change was 3.4, 4.3, and 3.4 months for RA, SLE, and DM/PM, respectively.
This study reports the real-world patient profile, use patterns, and outcomes of patients who used RCI for the treatment of RA, SLE, and DM/PM. These data can inform appropriate use and clinical expectations when using RCI.
Url:
DOI: 10.2147/OARRR.S231667
PubMed: 32110122
PubMed Central: 7039080
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000758
- to stream Pmc, to step Curation: 000758
- to stream Pmc, to step Checkpoint: 000009
- to stream Ncbi, to step Merge: 000F76
- to stream Ncbi, to step Curation: 000F76
- to stream Ncbi, to step Checkpoint: 000F76
- to stream Main, to step Merge: 000014
- to stream Main, to step Curation: 000014
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis</title>
<author><name sortKey="Ho Mahler, Nancy" sort="Ho Mahler, Nancy" uniqKey="Ho Mahler N" first="Nancy" last="Ho-Mahler">Nancy Ho-Mahler</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Mallinckrodt Pharmaceuticals</institution>
,<addr-line>Bedminster</addr-line>
,<addr-line>NJ</addr-line>
,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Turner, Beni" sort="Turner, Beni" uniqKey="Turner B" first="Beni" last="Turner">Beni Turner</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Xcenda</institution>
,<addr-line>Palm Harbor</addr-line>
,<addr-line>FL</addr-line>
,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Eaddy, Michael" sort="Eaddy, Michael" uniqKey="Eaddy M" first="Michael" last="Eaddy">Michael Eaddy</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Xcenda</institution>
,<addr-line>Palm Harbor</addr-line>
,<addr-line>FL</addr-line>
,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hanke, Mark L" sort="Hanke, Mark L" uniqKey="Hanke M" first="Mark L" last="Hanke">Mark L. Hanke</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Mallinckrodt Pharmaceuticals</institution>
,<addr-line>Bedminster</addr-line>
,<addr-line>NJ</addr-line>
,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nelson, Winnie W" sort="Nelson, Winnie W" uniqKey="Nelson W" first="Winnie W" last="Nelson">Winnie W. Nelson</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Mallinckrodt Pharmaceuticals</institution>
,<addr-line>Bedminster</addr-line>
,<addr-line>NJ</addr-line>
,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">32110122</idno>
<idno type="pmc">7039080</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039080</idno>
<idno type="RBID">PMC:7039080</idno>
<idno type="doi">10.2147/OARRR.S231667</idno>
<date when="2020">2020</date>
<idno type="wicri:Area/Pmc/Corpus">000758</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000758</idno>
<idno type="wicri:Area/Pmc/Curation">000758</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000758</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000009</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000009</idno>
<idno type="wicri:Area/Ncbi/Merge">000F76</idno>
<idno type="wicri:Area/Ncbi/Curation">000F76</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000F76</idno>
<idno type="wicri:Area/Main/Merge">000014</idno>
<idno type="wicri:Area/Main/Curation">000014</idno>
<idno type="wicri:Area/Main/Exploration">000014</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis</title>
<author><name sortKey="Ho Mahler, Nancy" sort="Ho Mahler, Nancy" uniqKey="Ho Mahler N" first="Nancy" last="Ho-Mahler">Nancy Ho-Mahler</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Mallinckrodt Pharmaceuticals</institution>
,<addr-line>Bedminster</addr-line>
,<addr-line>NJ</addr-line>
,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Turner, Beni" sort="Turner, Beni" uniqKey="Turner B" first="Beni" last="Turner">Beni Turner</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Xcenda</institution>
,<addr-line>Palm Harbor</addr-line>
,<addr-line>FL</addr-line>
,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Eaddy, Michael" sort="Eaddy, Michael" uniqKey="Eaddy M" first="Michael" last="Eaddy">Michael Eaddy</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Xcenda</institution>
,<addr-line>Palm Harbor</addr-line>
,<addr-line>FL</addr-line>
,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hanke, Mark L" sort="Hanke, Mark L" uniqKey="Hanke M" first="Mark L" last="Hanke">Mark L. Hanke</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Mallinckrodt Pharmaceuticals</institution>
,<addr-line>Bedminster</addr-line>
,<addr-line>NJ</addr-line>
,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nelson, Winnie W" sort="Nelson, Winnie W" uniqKey="Nelson W" first="Winnie W" last="Nelson">Winnie W. Nelson</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Mallinckrodt Pharmaceuticals</institution>
,<addr-line>Bedminster</addr-line>
,<addr-line>NJ</addr-line>
,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Open Access Rheumatology : Research and Reviews</title>
<idno type="eISSN">1179-156X</idno>
<imprint><date when="2020">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="S2001"><title>Purpose</title>
<p>Repository corticotropin injection (RCI) is indicated for a number of autoimmune-mediated diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and dermatomyositis (DM)/polymyositis (PM). To better understand the practice patterns and outcomes of RCI in patients with RA, SLE, or DM/PM, we conducted a retrospective medical record analysis.</p>
</sec>
<sec id="S2002"><title>Patients and Methods</title>
<p>Participating providers selected deidentified medical records of patients meeting the inclusion criteria (age ≥18 years; physician-reported diagnosis of RA, SLE, or DM/PM; initiation of treatment with RCI between 1/1/2011 and 2/15/2016; ≥3 in-office visits with same site/provider). Collected data spanned 12 months before and after the first prescription date for RCI. Analyses included patient demographics and clinical history, RCI treatment patterns, and physician’s impression of change.</p>
</sec>
<sec id="S2003"><title>Results</title>
<p>Data from 54 patients with RA, 30 patients with SLE, and 8 patients with DM/PM were analyzed. The most frequently reported reasons for initiating RCI were lack of efficacy with prior treatment, acute exacerbation of disease, and use as add-on to ongoing therapy. The most common initial RCI dosing, 80 U twice weekly, was used for 84% of patients with RA, 75% with SLE, and 86% with DM/PM. The mean duration of treatment was 4.8, 6.5, and 6.8 months for RA, SLE, and DM/PM, respectively. Among the 57 patients with data on physician’s impression of change with RCI, 78.1% of patients with RA, 94.7% with SLE, and 66.7% with DM/PM had a rating of “improved,” and the mean time to best impression of change was 3.4, 4.3, and 3.4 months for RA, SLE, and DM/PM, respectively.</p>
</sec>
<sec id="S2004"><title>Conclusion</title>
<p>This study reports the real-world patient profile, use patterns, and outcomes of patients who used RCI for the treatment of RA, SLE, and DM/PM. These data can inform appropriate use and clinical expectations when using RCI.</p>
</sec>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Ho Mahler, Nancy" sort="Ho Mahler, Nancy" uniqKey="Ho Mahler N" first="Nancy" last="Ho-Mahler">Nancy Ho-Mahler</name>
</noRegion>
<name sortKey="Eaddy, Michael" sort="Eaddy, Michael" uniqKey="Eaddy M" first="Michael" last="Eaddy">Michael Eaddy</name>
<name sortKey="Hanke, Mark L" sort="Hanke, Mark L" uniqKey="Hanke M" first="Mark L" last="Hanke">Mark L. Hanke</name>
<name sortKey="Nelson, Winnie W" sort="Nelson, Winnie W" uniqKey="Nelson W" first="Winnie W" last="Nelson">Winnie W. Nelson</name>
<name sortKey="Turner, Beni" sort="Turner, Beni" uniqKey="Turner B" first="Beni" last="Turner">Beni Turner</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000014 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000014 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Exploration |type= RBID |clé= PMC:7039080 |texte= Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32110122" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a ChloroquineV1
This area was generated with Dilib version V0.6.33. |